Within our relatively small series, this suggests that there may be a subset of people with AD who have more intense neurodegeneration, reflected by NfL, which may, therefore, complement P-tau biomarkers as a predictor of cognitive decline. The gene discussed is MAPT; the disease is Mental deterioration.